A new Deloitte report reveals that the pharmaceutical sector’s recent surge in R&D returns is largely driven by the booming demand for weight loss drugs like Wegovy and Zepbound. This concentration of success has created a ‘bubble effect,’ masking underlying weaknesses in other areas of the industry and increasing the risk of therapeutic-area-specific shocks.
For the first time in 16 years, obesity treatments have surpassed oncology as the largest contributor to late-stage pipeline value, highlighting the dramatic shift in the pharmaceutical landscape.
READ MORE FROM CNBC
Weight Loss Drugs Fuel Pharma Growth, But Risks Loom
Surging demand for weight loss and diabetes drugs like Wegovy and Zepbound is driving unprecedented growth in the pharmaceutical sector, but new research from Deloitte warns of a potential "bubble effect." While R&D returns have hit a 16-year high of 7%, this success is heavily concentrated in GLP-1 medications, masking a weaker performance across the rest of the industry.
Oncology No Longer Dominates R&D Pipeline
For the first time in 16 years, oncology is no longer the largest contributor to late-stage pipeline value, overtaken by obesity treatments. This shift increases companies’ vulnerability to therapeutic-area-specific setbacks.
Concentration of Risk
Currently, obesity assets account for approximately 38% of all projected commercial inflows from the 2025 late-stage pipeline, a dramatic increase from just 1% in 2022. However, excluding GLP-1/GIP assets, the industry's return on investment drops significantly to 2.9%, down from 3.8% in 2024. Deloitte highlights that just 54 mega-blockbuster indications, representing only 9% of the late-stage cohort, are projected to generate roughly 70% of total risk-adjusted peak sales.
The Future of GLP-1s and Beyond
Deloitte Partner Hanno Ronte emphasizes the need for continued innovation beyond GLP-1s, comparing the current situation to "riding a wave" with limited space. While ongoing research explores the potential benefits of GLP-1s in areas like cardiovascular health, Alzheimer's disease, and addiction, questions remain about their long-term effects and potential impact on brain health and inflammation. The success of these drugs has created a transformative market, but diversification is crucial to avoid overreliance on a single therapeutic area.
